Topics

Xencor Company Profile

02:58 EST 15th November 2019 | BioPortfolio

Since 1997, Xencor has built the most powerful protein engineering technology platform in the biotechnology industry. Its versatility is evidenced by our success in developing two classes of superior protein drug candidates: XmAb™ antibody therapeutics and XPro™ protein therapeutics. Because we can engineer the affinity and specificity of protein-protein interactions, we are also generating entirely new therapeutic mechanisms of action.In collaboration with our partners—including leading biotechnology company Genentech and pharmaceutical company Eli Lilly—we are selectively designing next-generation protein drug candidates with improved selectivity, efficacy and safety. Our internal pipeline of antibodies for cancer and protein therapeutics for inflammation and autoimmune disease address well understood and validated targets with potent new molecules. More than 40 talented scientists and the 8 industry veterans who make up our management team are working diligently to bring these drugs to the clinic and to deliver on the promise of protein-based medicines.

Location

111 West Lemon Avenue
Monrovia
California
91016
United States of America

Contact

Phone: 626-305-5900
Fax: 626-305-0350
Email: info@xencor.com


News Articles [32 Associated News Articles listed on BioPortfolio]

Xencor Shares Update on Phase 1 Study

Xencor announced the FDA lifted a partial clinical hold placed on its Phase 1 study of XmAb14045. The post Xencor Shares Update on Phase 1 Study appeared first on Investing News Network.

Xencor to Present at the 2019 Cantor Global Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, toda...

Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors

Through the early-stage trial called DUET-3, Xencor will assess the safety and tolerability of XmAb23104 in an estimated 144 patients with selected advanced solid tumors. The participants will The po...

Xencor to Participate in Upcoming Investor Conferences

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma an...

Xencor, Astellas Pharma collaborate on novel bispecific antibody program

As part of a research and license agreement, Astellas Pharma will be able to use Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology. The The post Xencor, Aste...

FDA lifts partial clinical hold on Xencor’s study of XmAb14045

The US Food and Drug Administration (FDA) has lifted the partial clinical hold placed on Xencor’s Phase I leukaemia study...Read More... The post FDA lifts partial clinical hold on Xencor’s study ...

Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma a...

Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma an...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Xencor Incorporated

Xencor™ is a biotechnology company that is commercializing Protein Design Automation™ (PDA), a proprietary research platform for protein design. PDA builds on recent groundbreaking advances in co...

Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to si...

Xencor

Since 1997, Xencor has built the most powerful protein engineering technology platform in the biotechnology industry. Its versatility is evidenced by our success in developing two classes of superior ...

More Information about "Xencor" on BioPortfolio

We have published hundreds of Xencor news stories on BioPortfolio along with dozens of Xencor Clinical Trials and PubMed Articles about Xencor for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Xencor Companies in our database. You can also find out about relevant Xencor Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record